Stock DNA
Pharmaceuticals & Biotechnology
CNY 7,971 Million (Mid Cap)
44.00
NA
1.04%
-0.27
7.65%
3.40
Revenue and Profits:
Net Sales:
309 Million
(Quarterly Results - Mar 2026)
Net Profit:
97 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.05%
0%
3.05%
6 Months
0.4%
0%
0.4%
1 Year
26.5%
0%
26.5%
2 Years
-14.81%
0%
-14.81%
3 Years
-56.1%
0%
-56.1%
4 Years
-85.85%
0%
-85.85%
5 Years
-72.43%
0%
-72.43%
Zhejiang Ausun Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.03%
EBIT Growth (5y)
12.45%
EBIT to Interest (avg)
62.16
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.28
Sales to Capital Employed (avg)
0.30
Tax Ratio
13.53%
Dividend Payout Ratio
40.14%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
16.62%
ROE (avg)
11.06%
Valuation key factors
Factor
Value
P/E Ratio
44
Industry P/E
Price to Book Value
3.44
EV to EBIT
48.29
EV to EBITDA
33.93
EV to Capital Employed
4.38
EV to Sales
9.95
PEG Ratio
NA
Dividend Yield
0.99%
ROCE (Latest)
9.06%
ROE (Latest)
7.84%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
308.70
146.80
110.29%
Operating Profit (PBDIT) excl Other Income
124.80
-69.50
279.57%
Interest
2.80
2.50
12.00%
Exceptional Items
-3.00
-0.50
-500.00%
Consolidate Net Profit
96.70
-76.50
226.41%
Operating Profit Margin (Excl OI)
404.20%
-607.30%
101.15%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 110.29% vs -10.54% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 226.41% vs -302.92% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
786.80
789.80
-0.38%
Operating Profit (PBDIT) excl Other Income
187.00
243.20
-23.11%
Interest
8.40
8.00
5.00%
Exceptional Items
-0.50
5.50
-109.09%
Consolidate Net Profit
130.60
206.80
-36.85%
Operating Profit Margin (Excl OI)
143.40%
227.40%
-8.40%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -0.38% vs -2.93% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -36.85% vs -18.55% in Dec 2024
About Zhejiang Ausun Pharmaceutical Co., Ltd. 
Zhejiang Ausun Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






